Thursday, January 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Elusys Delivers Anthrax Countermeasure Order, Gains Funding for Lyophilization Effort

by Global Biodefense Staff
February 2, 2017
Bacillus Anthracis

Elusys Therapeutics, Inc. has received payment from the U.S. federal government for completing the second delivery of its medical countermeasure for inhalational anthrax, according to a Jan. 24 statement by the company.

The $16.35 million fulfillment for delivery of ANTHIM® (obiltoxaximab) Injection is as part of a $45M procurement contract to provide ANTHIM for the U.S. Strategic National Stockpile. The company had previously received $8M for its first delivery of ANTHIM under this same contract earlier in 2016.

ANTHIM is a monoclonal antibody that binds to the protective antigen (PA) component of anthrax toxin. The countermeasure received U.S. Food and Drug Administration marketing approval in March 2016, for indications in both adult and pediatric patients for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.

Elusys also announced today that it has been awarded approximately $5M of additional funding from the Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, to continue Elusys’ lyophilization development program and regulatory activities to support a Supplemental BLA for a lyophilized form of ANTHIM.

The company has now received authorized funding from BARDA totaling more than $200M under two advanced development contracts for ANTHIM.

Tags: AnthraxASPRBioterrorismHHSSelect AgentsStrategic National Stockpile

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC